GSK posts strong growth thanks to Haleon spin-off and vaccines push
GSK beat market estimates in its fourth-quarter results and unveiled an upbeat forecast for 2024 and beyond on the acceleration of its vaccines and cancer drug pipeline.
POPULAR POSTS
LIVE STREAM
